840 results on '"Wu, Y.-L."'
Search Results
2. Prevalence and trend of gonorrhea in female sex workers and men having sex with men in China: a systematic review and meta-analysis
3. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
4. Bio-synthesis of molecularly imprinted membrane with photo-regeneration availability for selective separation applications
5. Toward the prevention of coronavirus infection: what role can polymers play?
6. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
7. 1279P First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study.
8. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
9. The prevalence and influencing factors for child neglect in a rural area of Anhui province: a 2-year follow-up study
10. 44P Exploratory analysis of peripheral pharmacodynamic (PD) biomarkers after sitravatinib (Sitra) and tislelizumab (TIS) in advanced solid tumors: SAFFRON-103
11. Molecular characterization of Blastocystis sp. in captive wild animals in Qinling Mountains
12. Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
13. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial
14. P4.17F.05 Adherence to Clinical Practice Guideline - Analysis of 89 Multidisciplinary Team Discussed Patients with Stage III Lung Cancer.
15. EP.17F.02 Three-Stage Evolution of Lung Cancer Multidisciplinary Team in China.
16. EP.15A.03 Lung Cancer Multidisciplinary Teams in China Show Multi-faceted Similarities and Differences Compared to Europe and Canada.
17. EP.12D.05 MAIC of OS and TRAE Comparing Capmatinib with Other MET Inhibitors for Treatment of Ansclc with MET Exon 14 Skipping Mutations.
18. EP.09B.03 Salvage Surgery Following Inductiontherapy for Advanced ALK-Positive NSCLC: Pathological Response and Surgical Outcomes.
19. EP.01D.02 Heterogeneous Germline Variants Detected in EGFR-Mutant Familial Lung Cancer Patients and Family Members.
20. P4.07E.07 Spatial Memory B Cells Activation by CXCL13+ Th Cells via the MIF(CD74-CXCR4) Axis may Improve Immunotherapy Efficacy in HER2 Mutant NSCLC.
21. P2.07C.03 Limited Efficacy of Immunochemotherapy in Pulmonary Invasive Mucinous Adenocarcinoma and Mucoepidermoid Carcinoma as Neoadjuvant Setting.
22. P1.06B.14 Optimal Cut-Off with NGS for Metamplification Andclinical Relevance to MET Inhibitor in Non-Small-Cell Lung Cancer.
23. P1.06A.04 Deep Learning-based Whole Slide Image Analysis Predicts PD-L1 Status from H&E-Stained Histopathology Images in Lung Cancer.
24. P1.03G.02 Genotyping of RB1 Status Identifies Two Distinct Subtypes in EGFR-Mutant Lung Cancers with SCLC Transformation.
25. MA15.11 Neoadjuvant Sintilimab plus Chemotherapy in EGFR-mutant NSCLC Followed by adjuvant Osimertinib or Observation: A Phase II CTONG2104 Trial.
26. OA06.03 SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1.
27. OA05.05 Pre-Local Consolidative Therapy Circulating Circulating Tumor DNA Defines Molecular Oligometastatic Non-Small Cell Lung Cancer.
28. PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC.
29. Supplement to: Osimertinib or platinum—pemetrexed in EGFR T790M—positive lung cancer.
30. EP.06G.18 Lung Cancer with Pleural Dissemination is Potentially a Non-Shedding Tumor
31. P4.11E.12 First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial
32. P1.08B.01 Predicting Tumor Recurrence Risk in Locally Advanced NSCLC with Detectable ctDNA-Based Molecular Residual Disease: An Xgboost Model Analysis
33. MA15.05 Follow-Up Update of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer
34. MA12.10 Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial
35. MA09.09 Genomic Mapping of Evolutionary from Pre-Invasive to Advanced Stage in Lung Adenocarcinoma
36. MA07.08 Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC
37. MA06.05 A Phase II Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-Treated with Crizotinib and Platinum-Based Chemotherapy
38. MA06.07 Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC
39. OA14.05 KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
40. OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
41. LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
42. 1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
43. 1315P BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in human phase I study in patients with advanced solid malignancies
44. 1272P Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
45. 1255MO A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
46. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
47. 997MO A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01
48. 642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC
49. LBA2 Phase II study of PD-L1 expression guidance on neoadjuvant (NA) nivolumab (Nivo) monotherapy with or without platinum-doublet chemotherapy in resectable NSCLC
50. LBA5 A phase II study of neoadjuvant SHR-1701 with or without chemotherapy (chemo) followed by surgery or radiotherapy (RT) in stage III unresectable NSCLC (uNSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.